<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287961</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS EP57 APACHES</org_study_id>
    <nct_id>NCT02287961</nct_id>
  </id_info>
  <brief_title>Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men</brief_title>
  <acronym>APACHES</acronym>
  <official_title>Natural History of Anal Human Papillomavirus Infection and Associated Disease in HIV-infected Men Who Have Sex With Men: Towards an Evidence Base for the Prevention of Anal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric epidemiological non-comparative study in France characterising evolution of anal&#xD;
      Human papillomavirus (HPV) infection and related lesions and evaluating markers associated&#xD;
      with the observed evolution.&#xD;
&#xD;
      Estimated enrolment: 500&#xD;
&#xD;
      Principal Outcomes&#xD;
&#xD;
        -  Detection of high-grade cytological and histological anal lesions by high resolution&#xD;
           anoscopy&#xD;
&#xD;
        -  Spontaneous regression of high-grade anal lesions&#xD;
&#xD;
        -  Detection of anal HPV infection&#xD;
&#xD;
      Intervention (procedure):&#xD;
&#xD;
        -  Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up&#xD;
           visits and if applicable Month 6 and Month 18 control visits)&#xD;
&#xD;
        -  Standard proctologic examination with digital rectal examination and 2 anal swabs&#xD;
           (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month&#xD;
           6 and Month 18 control visits)&#xD;
&#xD;
        -  High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up&#xD;
           visits and if applicable Month 6 and Month 18 control visits)&#xD;
&#xD;
      Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High&#xD;
      Resolution Anoscopy (HRA):&#xD;
&#xD;
      - anal biopsy(ies) during HRA&#xD;
&#xD;
      Only if high-grade lesion:&#xD;
&#xD;
      - HRA biannually&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention (procedure):&#xD;
&#xD;
        -  Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up&#xD;
           visits and if applicable Month 6 and Month 18 control visits)&#xD;
&#xD;
        -  Standard proctologic examination with digital rectal examination and 2 anal swabs&#xD;
           (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month&#xD;
           6 and Month 18 control visits)&#xD;
&#xD;
        -  High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up&#xD;
           visits and if applicable Month 6 and Month 18 control visits)&#xD;
&#xD;
      Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High&#xD;
      Resolution Anoscopy (HRA):&#xD;
&#xD;
      - anal biopsy(ies) during HRA&#xD;
&#xD;
      Only if high-grade lesion (Atypical squamous cells-cannot exclude high-grade squamous&#xD;
      intraepithelial lesion (ASC-H), High grade Superficial Intra-epithelial Lesion (HSIL) or&#xD;
      AIN2/3):&#xD;
&#xD;
      - HRA biannually&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of high-grade anal lesions by high resolution anoscopy</measure>
    <time_frame>Initial inclusion visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anal HPV infection by DNA, RNA and protein detection</measure>
    <time_frame>Initial inclusion visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of spontaneous regression of high-grade anal lesions</measure>
    <time_frame>Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of anal HPV infection by DNA, RNA and protein detection</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of anal HPV infection by DNA, RNA and protein detection</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of anal HPV infection by DNA, RNA and protein detection</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of anal HPV infection by DNA, RNA and protein detection</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hiv Infection</condition>
  <arm_group>
    <arm_group_label>Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits&#xD;
High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits&#xD;
Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy&#xD;
High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard proctologic examination</intervention_name>
    <description>(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High resolution anoscopy</intervention_name>
    <description>at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy(ies) during High Resolution Anoscopy</intervention_name>
    <description>only if lesion suggestive of AIN detected during High Resolution Anoscopy</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High Resolution Anoscopy biannually</intervention_name>
    <description>Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men who have sex with men&#xD;
&#xD;
          -  At least 35 years old&#xD;
&#xD;
          -  HIV-positive (documented search of HIV infection, with HIV status determined according&#xD;
             to HAS algorithm)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Affiliated to or beneficiary of French social security&#xD;
&#xD;
          -  All severity criteria and evolution of HIV disease are accepted (including AIDS stage&#xD;
             and co-infections)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to biopsy&#xD;
&#xD;
          -  History of anal cancer or pelvic radiotherapy&#xD;
&#xD;
          -  AIN2/3 treated during previous year&#xD;
&#xD;
          -  Current anticancer chemotherapy or within 24 months before inclusion&#xD;
&#xD;
          -  Difficulty in evaluation (anus reshaped and/or scarred)&#xD;
&#xD;
          -  Individual placed under judicial protection&#xD;
&#xD;
          -  Foreseen absence which may hamper participation; insufficient motivation; associated&#xD;
             pathology with priority for care&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Etienney</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital Diaconesses Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Clifford</last_name>
    <role>Study Director</role>
    <affiliation>International Agency for Research on Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diaconesses</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://anrs.fr</url>
    <description>Agence nationale de recherches sur le sida et les hÃ©patites virales (ANRS)</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

